Chris Slavinsky Email & Phone Number

New York, NY, US

Redwood City, CA, US

• Recruited by the President and CEO with a charter to transition the company from biosimilars into novel immuno-oncology therapeutics. Responsible for multiple functional areas including Business Development, Legal.
• Led cross-functional deal team and closed the acquisition of Surface Oncology (SURF), which added 2 clinical stage oncology candidates
• Launched YUSIMRY (bHUMIRA) into the highly competitive HUMIRA marketplace achieving target P&L performance, as well as created the partnership with the Mark Cuban Cost Plus Drug Company.
• Supported the successful commercial launch of CIMERLI (interchangeable bLUCENTIS); and then initiated the divestiture process for CIMERLI to support the company’s continuing strategic transformation.
• Supported the private placement of CHRS common stock (May 2023).
• Led patent strategy and execution, which included drafting and prosecuting patent applications in conjunction with external counsel.

• Recruited by the US CEO to serve as the strategic legal and compliance business partner to ensure the successful scale-up of the company and launch of MONOFERRIC, the first US single dose iron replacement therapeutic..
• Supported the successful launch of MONOFERRIC, which included commercial trade contracting, field sales and medical colleague training, and leading promotional review committee.
• Led acquisition of privately-held Abfero Pharmaceuticals, which expanded company’s iron-mediated disease candidate pipeline; assumed post-closing responsibility for IP portfolio management, clinical trial legal.
• Developed and implemented lobbying strategy regarding step therapy and access to medicines.

San Diego, California, US

• Recruited by the CEO with a charter to serve as Corporate Secretary and to lead the legal and business development functions. Responsible for legal, compliance, human resources, and quality assurance. Key Accomplishments
• Led and closed sell-side business development transactions forming foundational partnerships with Takeda and Dr. Falk Pharma.
• Supported Series C round of financing, including participating in non-deal road shows, and led drafting of corporate registration statement ahead of initial public offering (March 2021).
• Coordinated and led intellectual property strategy, creation, and protection in partnership with external counsel and collaboration partners (Cedars-Sinai, Takeda, Dr. Falk Pharma).
• Led human resources team through onset of COVID-19 pandemic restrictions, which included implementing a reduction in force and introducing week-on/week-off shifts for clinical lab personnel to mitigate potential.

Tokyo, JP

• Recruited by the Global Head, R&D Business Development to lead business development within Takeda’s largest therapeutic area (gastroenterology), divest non-core assets following the acquisition of Shire, and work.
• Led externalization activities across therapeutic areas, which included the formation of Phathom Pharmaceuticals (PHAT).
• Served as Takeda’s alliance management representative in strategic partnership with Kyoto University’s Center for iPSC Research and Application.
• Supported multinational patent litigation.

New York, New York, US

• CHIEF COUNSEL, PEH TRANSACTIONS (2009-2018)Recruited by the Chief Counsel, Pfizer Essential Health Business Unit (PEH) to lead and provide transactional legal support for PEH projects and generalist legal support.
• Negotiated and led M&A; exclusive license and asset purchase agreements; and asset divestitures.
• Led the successful integration of acquired businesses into PEH.CHIEF COUNSEL, MERIDIAN MEDICAL TECHNOLOGIES (2015-2018)Served as General Counsel for a wholly-owned subsidiary which: (a) manufactures and commercializes.

Philadelphia, PA, US

Chicago, US

Jd, Law

Ms, Biochemistry

Bs, Biochemistry